APEIRON Biologics AG

📍 Wien, Austria🗓 Founded 2003👥 15 employees💰 Last funded May 2015
Biotechnology Research🌐 apeiron-biologics.com
Website LinkedIn
APEIRON Biologics is a privately held European biotech company based in Vienna, Austria, focused on the discovery and development of treatments for respiratory diseases and novel cancer immunotherapies. Our company has a well balanced portfolio with one product on the market and several promising products from clinical to pre-clinical stages. As for the product on the market, APEIRON received EU marketing approval for APN311 (Dinutuximab beta, Qarziba®) in May 2017 for the treatment of pediatric neuroblastoma patients. We out-licensed Qarziba® globally to EUSA Pharma Ltd, for which it holds exclusive rights to this product. APEIRON’s key projects and technologies are bolstered by a strong patent portfolio with broad territorial coverage. Our development expertise is validated through partnerships with leading global pharmaceutical companies and academic institutions.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
2003
Founded

Investors

1 investor
All
Early stage
Mid stage
Late stage
Investor geography1 country
Austria
1
Frequently asked questions
Who invested in APEIRON Biologics AG?
APEIRON Biologics AG has 1 investor on record on gritt.io.
When did APEIRON Biologics AG last raise funding?
The most recent investment in APEIRON Biologics AG recorded on gritt.io was in May 2015.
When was APEIRON Biologics AG founded?
APEIRON Biologics AG was founded in 2003.
What industry is APEIRON Biologics AG in?
APEIRON Biologics AG operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is APEIRON Biologics AG based?
APEIRON Biologics AG is headquartered in Wien, Austria.